Piper Jaffray analyst William Quirk says channel checks found 10 Sequels placed in Q3, which suggests Pacific Biosciences had a sequential decline in placements, consistent with management comments. The analyst found 15 placements in his Q2 checks. Quirk trimmed his Q3 instrument expectations from 27 Sequels to 20 and his instrument revenue forecast by $2.2M to $6.4M. Despite being encouraged with the company’s continued progress on the 8M chip, he remains Neutral on the shares ahead of the earnings release.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.